Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:11:05 EDT Fri 26 Apr 2024
Enter Symbol
or Name
USA
CA



Q:ARWR - ARROWHEAD PHARMACEUTICALS INC - http://www.arrowheadresearch.net
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ARWR - Q2.421.75·22.460.122.12+0.251.1617.013,3146,25422.0899  22.36  21.7242.48  20.6719:22:2707:3015 min RT 2¢

Recent Trades - Last 10 of 6254
Time ETExPriceChangeVolume
19:22:27Q21.75-0.121
16:20:00Q22.120.25871
16:13:42Q22.120.2542
16:02:26Q22.120.252,621
16:02:24Q22.120.25160
16:02:20Q22.120.25122
16:02:14Q22.120.25306
16:02:12Q22.120.25337
16:01:52Q22.120.25202
16:01:29Q22.120.25257

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-26 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
2024-04-24 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
2024-04-24 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
2024-04-16 09:00U:ARWRNews ReleaseTurnstone Biologics Appoints William Waddill to its Board of Directors
2024-04-07 09:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
2024-04-01 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-25 08:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
2024-03-08 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
2024-03-04 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
2024-02-06 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
2024-01-22 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
2024-01-05 17:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
2024-01-03 07:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
2023-12-29 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-12-21 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
2023-12-20 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
2023-11-28 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
2023-11-21 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
2023-11-16 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results